Program
Levornidazole Disodium Phosphate for Injection
Its studies are mostly in Renal Insufficiency · Intraabdominal Infections, led by Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical.
Furthest: phase 4, since Feb 10, 20254 company-led studies, 0 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Yangtze River Pharmaceutical Group Jiangsu Zilong Pharmaceutical | 40 open or running | phase 4since Feb 10, 2025 | Feb 10, 2025 | none ahead |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 10, 2025First study: phase 4 study in Intraabdominal InfectionsFirst studyNCT06828874 · 696 enrolled · China
- Jun 13, 2025Phase 1 study in Renal InsufficiencyNCT07033182 · 24 enrolled · China
- Oct 22, 20262 phase 1 studiesNCT07906197, NCT07906171
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 4 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07906197Mass Balance Study · China | 1 | Completed | Dec 5, 2024 | 6 |
| NCT07906171Hepatic Impairment · China | 1 | Completed | Sep 21, 2024 | 25 |
| NCT07033182Renal Insufficiency · China | 1 | Completed | Apr 7, 2024 | 24 |
| NCT06828874Intraabdominal Infections · China | 4 | Completed | Sep 23, 2024 | 696 |
How it is read
Names in the registry
- “Levornidazole Disodium Phosphate for Injection”, 6 entries
Conditions, from the studies’ own filings
- Renal Insufficiency, 1 study
- Intraabdominal Infections, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.